Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Ovarian Cancer Treatment Stratification Using Ex Vivo Drug Sensitivity Testing.

Lohse I, Azzam DJ, Al-Ali H, Volmar CH, Brothers SP, Ince TA, Wahlestedt C.

Anticancer Res. 2019 Aug;39(8):4023-4030. doi: 10.21873/anticanres.13558.

PMID:
31366484
2.

Dual Src and MEK Inhibition Decreases Ovarian Cancer Growth and Targets Tumor Initiating Stem-Like Cells.

Simpkins F, Jang K, Yoon H, Hew KE, Kim M, Azzam DJ, Sun J, Zhao D, Ince TA, Liu W, Guo W, Wei Z, Zhang G, Mills GB, Slingerland JM.

Clin Cancer Res. 2018 Oct 1;24(19):4874-4886. doi: 10.1158/1078-0432.CCR-17-3697. Epub 2018 Jun 29.

3.

A New Role for ERα: Silencing via DNA Methylation of Basal, Stem Cell, and EMT Genes.

Ariazi EA, Taylor JC, Black MA, Nicolas E, Slifker MJ, Azzam DJ, Boyd J.

Mol Cancer Res. 2017 Feb;15(2):152-164. doi: 10.1158/1541-7786.MCR-16-0283. Epub 2016 Nov 15.

4.

Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer.

Witt AE, Lee CW, Lee TI, Azzam DJ, Wang B, Caslini C, Petrocca F, Grosso J, Jones M, Cohick EB, Gropper AB, Wahlestedt C, Richardson AL, Shiekhattar R, Young RA, Ince TA.

Oncogene. 2017 Mar 23;36(12):1707-1720. doi: 10.1038/onc.2016.337. Epub 2016 Oct 3.

5.

Interactions between Adipocytes and Breast Cancer Cells Stimulate Cytokine Production and Drive Src/Sox2/miR-302b-Mediated Malignant Progression.

Picon-Ruiz M, Pan C, Drews-Elger K, Jang K, Besser AH, Zhao D, Morata-Tarifa C, Kim M, Ince TA, Azzam DJ, Wander SA, Wang B, Ergonul B, Datar RH, Cote RJ, Howard GA, El-Ashry D, Torné-Poyatos P, Marchal JA, Slingerland JM.

Cancer Res. 2016 Jan 15;76(2):491-504. doi: 10.1158/0008-5472.CAN-15-0927. Epub 2016 Jan 7.

6.

Exosome transfer from stromal to breast cancer cells regulates therapy resistance pathways.

Boelens MC, Wu TJ, Nabet BY, Xu B, Qiu Y, Yoon T, Azzam DJ, Twyman-Saint Victor C, Wiemann BZ, Ishwaran H, Ter Brugge PJ, Jonkers J, Slingerland J, Minn AJ.

Cell. 2014 Oct 23;159(3):499-513. doi: 10.1016/j.cell.2014.09.051.

7.

VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2.

Zhao D, Pan C, Sun J, Gilbert C, Drews-Elger K, Azzam DJ, Picon-Ruiz M, Kim M, Ullmer W, El-Ashry D, Creighton CJ, Slingerland JM.

Oncogene. 2015 Jun 11;34(24):3107-19. doi: 10.1038/onc.2014.257. Epub 2014 Aug 25.

PMID:
25151964
8.

Primary breast tumor-derived cellular models: characterization of tumorigenic, metastatic, and cancer-associated fibroblasts in dissociated tumor (DT) cultures.

Drews-Elger K, Brinkman JA, Miller P, Shah SH, Harrell JC, da Silva TG, Ao Z, Schlater A, Azzam DJ, Diehl K, Thomas D, Slingerland JM, Perou CM, Lippman ME, El-Ashry D.

Breast Cancer Res Treat. 2014 Apr;144(3):503-17. doi: 10.1007/s10549-014-2887-9. Epub 2014 Feb 25.

PMID:
24567196
9.

Triple negative breast cancer initiating cell subsets differ in functional and molecular characteristics and in γ-secretase inhibitor drug responses.

Azzam DJ, Zhao D, Sun J, Minn AJ, Ranganathan P, Drews-Elger K, Han X, Picon-Ruiz M, Gilbert CA, Wander SA, Capobianco AJ, El-Ashry D, Slingerland JM.

EMBO Mol Med. 2013 Oct;5(10):1502-22. doi: 10.1002/emmm.201302558. Epub 2013 Aug 27.

10.

High-performance liquid chromatography method for quantifying sphingomyelin in rat brain.

Azzam DJ, Usta JA, Mouneimne Y, El Hokayem JA, Mikati MA.

J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Nov 1;859(1):131-6. Epub 2007 Sep 14.

PMID:
17901003

Supplemental Content

Loading ...
Support Center